

## Recurrent SARS-CoV-2 RNA Detection after COVID-19 Illness Onset during Pregnancy

Isabel Griffin, Kate R. Woodworth, Romeo R. Galang, Veronica K. Burkel, Varsha Neelam, Samantha Siebman, Jerusha Barton, Susan E. Manning, Kathryn Aveni, Nicole D. Longcore, Elizabeth M. Harvey, Van Ngo, Deborah Mbotha, Sarah Chicchelly, Mamie Lush, Valorie Eckert, Paula Dzimira, Ayomide Sokale, Miguel Valencia-Prado, Eduardo Azziz-Baumgartner, Adam MacNeil, Suzanne M. Gilboa, Van T. Tong

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (I. Griffin, K.R. Woodworth, R.R. Galang, V.K. Burkel, V. Neelam, E. Azziz-Baumgartner, A. MacNeil, S.M. Gilboa, V.T. Tong); Minnesota Department of Health, St. Paul, Minnesota, USA (S. Siebman); Georgia Department of Public Health, Atlanta (J. Barton); Massachusetts Department of Public Health, Boston, Massachusetts, USA (S.E. Manning); New Jersey Department of Health, Trenton, New Jersey, USA (K. Aveni); New York State Department of Health, Albany, New York, USA (N.D. Longcore); Tennessee Department of Health, Smithville, Tennessee, USA (E.M. Harvey); Los Angeles County Department of Public Health, Los Angeles, California, USA (V. Ngo); Washington State Department of Health, Tumwater, Washington, USA (D. Mbotha); Kansas Department of Public Health, Wichita, Kansas, USA (S. Chicchelly); Nebraska Department of Health and Human Services, Lincoln, Nebraska, USA (M. Lush); California Department of Public Health, Sacramento, California, USA (V. Eckert); Pennsylvania Department of Health, Harrisburg, Pennsylvania, USA (P. Dzimira); Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA (A. Sokale); Puerto Rico Department of Health, Bo. Monacillos Río Piedras, Puerto Rico, USA (M. Valencia-Prado)

DOI: <https://doi.org/10.3201/eid2804.212354>

The Surveillance for Emerging Threats to Mothers and Babies Network conducts longitudinal surveillance of pregnant persons in the United States with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection during pregnancy. Of 6,551 infected pregnant persons in this analysis, 142 (2.2%) had positive RNA tests >90 days and up to 416 days after infection.

**D**etection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in respiratory specimens that recurs over extended time intervals might indicate viral RNA persistence, continued

viral replication, reinfection, or sample testing error (1). Although SARS-CoV-2 infections are generally acute, persistent detection of RNA in upper respiratory specimens has been described with a mean duration of 17 days and detectable RNA for up to 12 weeks after symptom onset among recovered patients (2–5). Virus detection has been reported in severely immunocompromised patients beyond 20 days and up to 143 days after an initial positive SARS-CoV-2 test result (3,4). SARS-CoV-2 reinfections documented through whole-genome sequencing are rare (6).

Immunologic changes during pregnancy might increase risk of SARS-CoV-2 infection, susceptibility to severe illness, and viral shedding (7). A cohort study identified several pregnant persons who tested positive 90 days after an initial positive test (8). The objective of our study was to describe demographic and clinical characteristics overall and by recurrent test-positive status in a convenience sample of pregnant persons with SARS-CoV-2 infection laboratory confirmed by molecular amplification detection testing (9). This exploratory analysis includes data reported from 21 jurisdictions to the Surveillance for Emerging Threats to Mothers and Babies Network; first positive reverse transcription PCR (RT-PCR) results during pregnancy occurred during March 29, 2020–December 31, 2020, with data reported through September 3, 2021.

We enrolled pregnant persons who met our inclusion criteria (Appendix, <https://wwwnc.cdc.gov/EID/article/28/4/21-2354-App1.pdf>). We defined persons with an RT-PCR-positive respiratory specimen collected >90 days after symptom onset as recurrent positive (RP) independent of the presence of any intermittent RT-PCR-negative specimens. Persons who did not meet the RP definition were labeled not recurrent (NR). However, not all persons received follow-up testing, and additional laboratory results were voluntarily reported. Duration of RT-PCR positivity was defined as the number of days from symptom onset until the last known positive RT-PCR in a respiratory specimen. Duration of RNA shedding was defined as the number of days from symptom onset until the second consecutive negative SARS-CoV-2 result by RT-PCR among pregnant persons reported with a follow-up test. Testing was not routine, and this factor likely will overestimate length of RNA shedding.

Among 6,551 pregnant persons (median age 29 years; 39.7% non-Hispanic White) in our analysis, 17.5% had first trimester infections, 35.5% second, and 47.0% third (Table). Median duration of RT-PCR positivity was 3 days (range 0–416 days). Overall, we collected 9,985 respiratory specimens with RT-PCR results (which could

**Table.** Symptomatic pregnant persons with SARS-CoV-2 infection detected in respiratory specimens by recurrent positive status, based on RT-PCR positive test result >90 d after symptom onset, Surveillance for Emerging Threats to Mothers and Babies Network, United States, March 29–December 31, 2020\*

Characteristic	Total, N = 6,551	Not recurrent, n = 6,409	Recurrent positive, n = 142
Median duration of RT-PCR positivity (range), d	3 (0–416)	3 (0–90)	127 (91–416)
Median duration of RNA shedding (range), d†	135 (0–441)	148 (0–441)	143 (18–412)
Median age at first positive result (IQR), y	29 (25–33)	29 (25–33)	29 (25–32)
Age at initial infection, y‡			
<25	1,547 (23.6)	1,512 (23.6)	35 (25.6)
25–29	2,034 (31.0)	1,990 (31.0)	44 (40.0)
30–34	1,857 (28.4)	1,809 (28.2)	48 (33.8)
>35	1,113 (17.0)	1,098 (17.1)	15 (10.6)
Race/ethnicity			
White non-Hispanic	2,599 (39.7)	2,554 (39.8)	45 (31.7)
Asian non-Hispanic	275 (4.2)	270 (4.2)	5 (3.5)
Black non-Hispanic	1,197 (18.3)	1,171 (18.3)	26 (18.3)
Hispanic	2,077 (31.7)	2,029 (31.7)	48 (33.8)
Multiple or other non-Hispanic	210 (3.2)	200 (3.1)	10 (7.1)
Unknown	193 (2.9)	185 (2.9)	8 (5.6)
Trimester of SARS-CoV-2 infection§			
First	1,146 (17.5)	1,114 (17.4)	32 (22.5)
Second	2,327 (35.5)	2,231 (34.8)	96 (67.6)
Third	3,078 (47.0)	3,064 (47.8)	14 (9.9)
Underlying conditions¶			
Yes	4,945 (74.4)	4,478 (25.6)	10 (7.0)
No	1,488 (22.7)	4,184 (72.4)	131 (92.3)
Unknown	118 (1.8)	117 (2.0)	1 (0.7)

\*Values are no. (%) except as indicated. IQR, interquartile range; RT-PCR, reverse transcription PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

†Duration of RNA shedding was available for only 458 persons.

‡Age in years at initial infection was calculated based on date of first SARS-CoV-2–positive test result during pregnancy or symptom onset if date of positive is unavailable.

§Trimester of SARS-CoV-2 infection is calculated based on date of last menstrual period and either date of first positive SARS-CoV-2 results or symptom onset if date of positive unavailable.

¶Presence of any underlying condition was defined as any of the following: obesity, chronic lung disease, hypertension, diabetes, cardiovascular disease, or immunosuppressive conditions (conditions that weaken the immune system [e.g., HIV or AIDS, some cancers such as leukemia] or medications [e.g., chemotherapy or radiation treatment, chronic corticosteroids, or other immunosuppressive medications]).


include multiple positive, negative, or indeterminate results per person); 12.5% of specimens tested 90 days after initial symptom onset were positive (158/1,257 specimens) and 9.2% of specimens tested 330 days after initial symptom onset were positive (6/65 specimens). Median duration of documented RNA shedding per person was 130 days (range 0–441 days; n = 458).

Overall, 142 persons (2.2%) from 14 jurisdictions met the RP definition. Among 6,409 NR persons, 727 (11.3%) were RT-PCR–negative after 90 days; 5,682 (88.6%) did not have any known RT-PCR results after 90 days. Several RPs were positive by RT-PCR in respiratory specimens for up to 330 days after symptom onset (Figure). Comparing RP to NR persons identified small differences in age group, race/ethnicity, and trimester of infection (Table). A higher percentage of RPs (33.8%) than NRs (28.2%) were 30–34 years of age. Non-Hispanic White persons made up 39.8% of NRs compared with 31.7% of RPs; most RPs were Hispanic (33.8%) and non-Hispanic Black (18.3%). Most RPs had second trimester infections (67.6%), whereas most NRs had third trimester infections (47.8%).

Our study's first limitation is that SARS-CoV-2 genetic sequencing was not reported; reinfection

could not be distinguished from recurrent viral shedding. A positive RT-PCR result alone without other information (data on symptom onset, cycle threshold, or viral culture) cannot distinguish infectious virus from noninfectious genomic fragments. Second, health departments were not required to send laboratory testing beyond the first positive result that occurred during pregnancy; these findings are from a convenience sample of pregnant persons with varied duration of follow-up and do not estimate the actual extent of recurrent positivity. Furthermore, persons with infections earlier in pregnancy might be more likely to be classified as RP, given that they can be followed longer and receive additional COVID-19 testing compared with persons with initial symptom onset later in pregnancy. Last, only 31.4% of our cohort (n = 2,062) had multiple test results, representing a small proportion of pregnant persons.

The findings of this report suggest that specimens from pregnant persons diagnosed with symptomatic SARS-CoV-2 infections might be recurrently positive for up to 416 days after symptom onset. Future prospective cohort studies among pregnant persons with SARS-CoV-2 testing should be performed over



**Figure.** Timing of all known respiratory reverse transcription PCR (RT-PCR) results among recurrent positive pregnant persons (positive test result >90 days from reported symptom onset). Surveillance for Emerging Threats to Mothers and Babies Network, United States, March 29, 2020–December 31, 2020 (n = 142). Data reported as of September 3, 2021. Case ID 4 had positive and negative respiratory RT-PCR tests on day 114; case ID 20 had positive and negative respiratory RT-PCR tests on day 160; case ID 107 had positive and negative respiratory RT-PCR tests on day 186; case ID 135 had positive and negative respiratory RT-PCR tests on days 382 and 389; case ID 139 had positive and negative respiratory RT-PCR tests on day 204. Indeterminate result was defined as one that might indicate the presence of viral RNA but not enough to be considered positive. ID, identification.

consistent lengths of time, distinguish infectious viral shedding from noninfectious recurrent positive PCR results, and examine risk of reinfection during pregnancy given the recent emergence of new coronavirus disease variants. Longitudinal surveillance of pregnant persons with COVID-19 can be used for hypothesis generation, in addition to monitoring the impact of infection on pregnancy and infant outcomes.

### Acknowledgments

We thank our Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET) jurisdictional partners: California Department of Public Health (Valorie Eckert, Barbara Warmerdam, Similoluwa Sowunmi, Olga Barer), Georgia Department of Public Health (J. Michael Bryan, Cristina Meza, Victoria Sanon, Teri' Willabus, Cynthia Carpentieri, Michael Andrews, Sashawn Lawrence, Camille Millar), Houston Health Department, Iowa Department of Public Health, Kansas Department of Public Health, Los Angeles County Department of Public Health (Umme-Aiman

Halai, Caleb Lu, Emily Barnes, Alison Ryan, Nina Mykhaylov), Massachusetts Department of Public Health (Eirini Nestoridi, Hanna Shephard, Mahsa Yazdy, Catherine Brown), Michigan Department of Health and Human Services, Minnesota Department of Health, Nebraska Department of Health and Human Services (Tyler Faulkner, Samir Koirala, Ronda Simpson, Shannon Lawrence), Nevada Department of Health and Human Services, New Jersey Department of Health and Senior Services (Shoshana Merzel), New Hampshire Department of Health and Human Services, New York State Department of Health (Zahra S. Alaali, Nadia Thomas, Pauline Santos), Pennsylvania Department of Health, Philadelphia Department of Public Health (My-Phuong Huynh), Puerto Rico Department of Health (Camille Delgado-López, Mariam Marcano-Huertas, Leishla Nieves-Ferrer), South Carolina Department of Health and Environmental Control, Tennessee Department of Health (Lindsey Sizemore, Heather Wingate), US Virgin Islands Department of Health, and Washington State Department of Health. We would also like to acknowledge our colleagues

in the COVID-19 Pregnancy and Infant Linked Outcomes Team (PILOT) (Elizabeth Lewis, Amanda Akosa, Nicki Roth, Christina Sancken, Megan Reynolds).

### About the Author

Dr. Griffin is a contracted epidemiologist with Eagle Global Scientific, LLC, in the National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, in Atlanta, Georgia, USA. Her primary research interest is emerging infectious diseases.

### References

1. Tang X, Musa SS, Zhao S, He D. Reinfection or reactivation of severe acute respiratory syndrome coronavirus 2: a systematic review. *Front Public Health*. 2021;9:663045. <https://doi.org/10.3389/fpubh.2021.663045>
2. Cevik M, Tate M, Lloyd O, Enrico Maraolo A, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe*. 2021;2:e13–22. [https://doi.org/10.1016/S2666-5247\(20\)30172-5](https://doi.org/10.1016/S2666-5247(20)30172-5)
3. Abu-Raddad LJ, Chemaitelly H, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. *EClinicalMedicine*. 2021;35:100861. <https://doi.org/10.1016/j.eclinm.2021.100861>
4. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. *N Engl J Med*. 2020;383:2291–3. <https://doi.org/10.1056/NEJMc2031364>
5. Centers for Disease Control and Prevention. Interim guidance on ending isolation and precautions for adults with COVID-19. 2021 Mar 16 [cited 2021 Jun 28]. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>
6. Rodríguez-Grande C, Alcalá L, Estévez A, Sola-Campoy PJ, Buenestado-Serrano S, Martínez-Laperche C, et al.; Gregorio Marañón Microbiology-ID COVID 19 Study Group. Systematic genomic and clinical analysis of severe acute respiratory syndrome coronavirus 2 reinfections and recurrences involving the same strain. *Emerg Infect Dis*. 2022;28:85–94. <https://doi.org/10.3201/eid2801.211952>
7. Donders F, Lonnée-Hoffmann R, Tsiakalos A, Mendling W, Martinez de Oliveira J, Judlin P, et al.; Isidog Covid-Guideline Workgroup. ISIDOG recommendations concerning COVID-19 and pregnancy. *Diagnostics (Basel)*. 2020;10:243. <https://doi.org/10.3390/diagnostics10040243>
8. Dubelbeiss E, Silverberg M, White C, Jaspan D, Goldberg J, Haines C. Repeat positive severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019) testing  $\geq 90$  days apart in pregnant women. *Am J Obstet Gynecol MFM*. 2021;3:100331. <https://doi.org/10.1016/j.ajogmf.2021.100331>
9. Woodworth KR, Reynolds MR, Burkel V, Gates C, Eckert V, McDermott C, et al. A preparedness model for mother-baby linked longitudinal surveillance for emerging threats. *Matern Child Health J*. 2021;25:198–206. <https://doi.org/10.1007/s10995-020-03106-y>

Address for correspondence: Kate R. Woodworth, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop S 106-3, Atlanta, GA 30341, USA; email: eoevent397@cdc.gov

## Hantavirus Pulmonary Syndrome in a COVID-19 Patient, Argentina, 2020

Rocío M. Coelho, Natalia Periolo, Carolina Perez Duhalde, Daniel O. Alonso, Carla M. Bellomo, Marisa Corazza, Ayelén A. Iglesias, Valeria P. Martinez

Author affiliations: Administración Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbrán, Buenos Aires, Argentina (R.M. Coelho, N. Periolo, D.O. Alonso, C.M. Bellomo, A.A. Iglesias, V.P. Martinez); Hospital Interzonal General de Agudos General de San Martín, Buenos Aires (C. Perez Duhalde); Instituto Biológico “Tomás Perón,” Buenos Aires (M. Corazza)

DOI: <https://doi.org/10.3201/eid2804.211837>

We describe a patient in Argentina with severe acute respiratory syndrome coronavirus 2 infection and hantavirus pulmonary syndrome (HPS). Although both coronavirus disease and HPS can be fatal when not diagnosed and treated promptly, HPS is much more lethal. This case report may contribute to improved detection of co-infections in HPS-endemic regions.

The current coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in substantial illness and death rates worldwide. Orthohantaviruses are zoonotic viruses responsible for another severe respiratory infectious disease in the Americas, hantavirus pulmonary syndrome (HPS). Although humans generally become infected with HPS through inhaling excreta generated by infected rodents, person-to-person transmission has been well documented in Argentina and Chile (1–3). Humans become infected with SARS-CoV-2 and orthohantaviruses in similar ways, through inhaling contaminated aerosols, and can have onset of similar respiratory syndromes. Despite these similarities, the incubation period is shorter in COVID-19 patients (2–14 days) than in HPS patients (7–45 days). Furthermore, at the time the case we describe was reported, the cumulative case-fatality rate for COVID-19 in Argentina was 2.7% (4); for HPS, it was 22%–40% (5).

HPS is characterized by the onset of symptoms such as fever, myalgia, cough, dyspnea, diarrhea, and sweating. Rapid progression to shock or respiratory distress can occur within hours. Symptom-based

<sup>†</sup>These authors contributed equally to this article.

# Recurrent SARS-CoV-2 RNA Detection after COVID-19 Illness Onset During Pregnancy

## Appendix

### Supplemental Methods

Study inclusion criteria were 1) first reverse transcription PCR (RT-PCR)–positive respiratory specimen taken during pregnancy, 2) age of 10–53 years, 3) known coronavirus disease symptom onset date, 4) known trimester of infection, and 5) known date of first positive respiratory specimen. This activity was reviewed by the Centers for Disease Control and Prevention, determined to be a nonresearch, public health surveillance activity, and was conducted consistent with applicable federal law and Centers for Disease Control and Prevention policy (1).

### Supplemental Results

Seven percent (7.0%) of recurrent positive (RP) persons had >1 underlying condition (obesity, chronic lung disease, hypertension, diabetes, cardiovascular disease, or immunosuppressive condition) compared with 25.6% of not recurrent persons (Table in main text, <https://wwwnc.cdc.gov/EID/article/28/4/21-2354-T1.htm>). We hypothesized that RP persons would have other underlying conditions that would affect their immune status besides pregnancy, but this finding could also be explained by the fact that the not recurrent cohort likely contained some undetected RPs. In all but 1 of the 142 RP persons, symptom onset occurred before known circulation (December 20, 2020) of severe acute respiratory syndrome coronavirus 2 variants of interest or concern (2).

## References

1. Department of Health and Human Services. 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq [cited 2021 Feb 4].  
<https://www.hhs.gov/ohrp/sites/default/files/ohrp/policy/ohrpreulations.pdf>
2. Paul P, France AM, Aoki Y, Batra D, Biggerstaff M, Dugan V, et al. Genomic surveillance for SARS-CoV-2 variants circulating in the United States, December 2020–May 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70:846–50. [PubMed https://doi.org/10.15585/mmwr.mm7023a3](https://doi.org/10.15585/mmwr.mm7023a3)